Department of Cardiovascular Medicine, The Western Galilee Hospital in Nahariya, Nahariya; Faculty of Medicine of the Galilee, Bar Ilan University, Safed.
Department of Cardiovascular Medicine, The Western Galilee Hospital in Nahariya, Nahariya.
Chest. 2013 Jul;144(1):327-328. doi: 10.1378/chest.12-2486.
Several new oral anticoagulants have been approved for thromboembolism prevention in patients with nonvalvular atrial fibrillation. However, they are not yet approved for anticoagulation use in patients with prosthetic mechanical valves, and no randomized data have been published so far on their safety of use in these patients. We present two cases of patients with prosthetic mechanical mitral valves who were switched from warfarin and acenocoumarol to dabigatran and within 1 month experienced severe valve complications resulting in death. One patient experienced stroke and later cardiogenic shock and death, and the other experienced pulmonary edema, cardiogenic shock, and subsequent death.
几种新的口服抗凝剂已获准用于预防非瓣膜性心房颤动患者的血栓栓塞。然而，它们尚未获准用于患有机械性人工心脏瓣膜的患者的抗凝治疗，目前也尚未发表关于这些患者使用安全性的随机数据。我们报告了两例患有机械性二尖瓣人工瓣膜的患者，他们从华法林和醋硝香豆素转换为达比加群，在 1 个月内发生严重的瓣膜并发症，导致死亡。一名患者发生了中风，随后发生心源性休克和死亡，另一名患者发生了肺水肿、心源性休克和随后的死亡。
